Trading in AstraZeneca‘s (NASDAQ: AZN) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session. With that rise, it did better than the S&P 500 (SNPINDEX: ^GSPC), which closed the day marginally (0.1%) lower.
That morning, U.K. newspaper The Times published an article stating that AstraZeneca CEO Pascal Soriot aims to move the company’s stock market listing onto our shores (ADSes are certificates conferring ownership of a stock, not the stock itself).
Image source: Getty Images.